Japan’s MoF seen as another opponent to premium system
The Budget Bureau of Japan’s Ministry of Finance (MoF), in a meeting of the Fiscal System Council (FSC) last week, criticized the Ministry of Health, Labor and Welfare (MHLW) for poor control of medical expenditure, reports The Pharma Letter’s local analyst.
The MoF was preparing its budget policy for next year in relation to the biannual revision of the National Health Insurance (NHI) reimbursement prices slated for April 2014. The Budget Bureau expressed its concern about the premium system that had made a half of patented drugs exempt from biannual price cuts.
The government’s budget planner was of the opinion that the drugs receiving the premium were not necessarily innovative and that not all the companies with premium drugs were sponsoring clinical and regulatory works on ignored (but essential) drugs as the industry had pledged.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze